Drug Trial Radar · NCT03164564
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,224
Actual
Start
Nov 7, 2017
Primary completion
Nov 5, 2020
Study completion Oct 17, 2026
Sponsor
- Sponsor type
- NIH
- First posted
- May 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.
Conditions
- HIV Infections
Interventions
Oral CABDrug
CAB 30 mg tablet
Oral TDF/FTCDrug
TDF/FTC 300 mg/200 mg fixed dose combination tablet
Placebo for oral CABDrug
Placebo tablets
Placebo for oral TDF/FTCDrug
Placebo tablets
CAB LADrug
600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Placebo for CAB LADrug
Administered as one 3 mL intramuscular injection in the gluteal muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Pariicipants With Documented Incident HIV InfectionsTime frame: HIV tests at enrollment, weeks 2, 4, and 5, then every 4 weeks through week 25, then every 8 weeks. Analyzed through week 185 or the date of DSMB decision to unblind all participants, whichever is earliest.
- Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2Time frame: Treatment emergent AE measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks)
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Gaborone CRS
Gaborone, South-East District, Botswana
Eswatini Prevention Center CRS
Mbabane, Eswatini
Kisumu Crs
Kisumu, Nyanza, Kenya
Blantyre CRS
Blantyre, Malawi
Malawi CRS
Lilongwe, Central Region, Malawi
Soweto HPTN CRS
Johannesburg, Gauteng, South Africa
Ward 21 CRS
Johannesburg, Gauteng, South Africa
Botha's Hill CRS
Durban, KwaZulu-Natal, South Africa
Isipingo CRS
Isipingo, KwaZulu-Natal, South Africa
Verulam CRS
Verulam, KwaZulu-Natal, South Africa
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, South Africa
Emavundleni CRS
Cape Town, Western Cape, South Africa
UVRI-IAVI HIV Vaccine Program LTD. CRS
Entebbe, Uganda
Baylor-Uganda CRS
Kampala, Uganda
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
Kampala, Uganda
Seke South CRS
Chitungwiza, Zimbabwe
St Mary's CRS
Chitungwiza, Zimbabwe
Milton Park CRS
Harare, Zimbabwe
Spilhaus CRS
Harare, Zimbabwe
Zengeza CRS
Chitungwiza, Mashonaland East Province, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.